Copyright 2009 Medical News Today Latest Clinical Trials / Drug Trials News From Medical News Today. http://www.medicalnewstoday.com/sections/clinical_trials/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Sat, 07 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/170190.php http://www.medicalnewstoday.com/articles/170190.php CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today that an Institutional Review Board of The Johns Hopkins University School of Medicine (Johns Hopkins) has given clearance for the Company's first clinical study to proceed. As a result, Johns Hopkins will host the study, which will be led by Principal Investigator Jonathan M. Swine Flu Sat, 07 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/170191.php http://www.medicalnewstoday.com/articles/170191.php Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). Dermatology Sat, 07 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/170192.php http://www.medicalnewstoday.com/articles/170192.php Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. Lung Cancer Sat, 07 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/170203.php http://www.medicalnewstoday.com/articles/170203.php H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase IIa clinical studies with the innovative project Lu AA24493 in order to evaluate safety and tolerability and to explore theoretical efficacy parameters of the drug in humans. Lundbeck expects to enrol 35-40 people suffering from Friedreich's ataxia in this study. Neurology / Neuroscience Sat, 07 Nov 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/170124.php http://www.medicalnewstoday.com/articles/170124.php For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options. Lymphoma / Leukemia / Myeloma Fri, 06 Nov 2009 21:00:00 PST http://www.medicalnewstoday.com/articles/170156.php http://www.medicalnewstoday.com/articles/170156.php ERYtech Pharma announces the start of its pivotal clinical trial for GRASPA®, its lead product in Acute Lymphoblastic Leukaemia. This phase III trial has begun in France and will be enlarged to a European scale. Up to 80 patients with relapsed Acute Lymphoblastic Leukaemia, aged from 1 to 55 years old will be enrolled. The endpoint combines safety and efficacy with regard to the asparagine depletion level. Lymphoma / Leukemia / Myeloma Fri, 06 Nov 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/170062.php http://www.medicalnewstoday.com/articles/170062.php An experimental vaccine to treat precancerous vulvar growths eliminated the growths in nine of 20 women participating in a small trial, according to a study published in the New England Journal of Medicine, Reuters reports. Women's Health / Gynecology Fri, 06 Nov 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/170142.php http://www.medicalnewstoday.com/articles/170142.php The Cornea and Laser Eye Institute is participating in a research study to determine if an investigational corneal inlay can safely and effectively reduce the need for reading glasses. Dr. Peter Hersh, the study doctor, will perform the procedures. The investigational AcuFocus Corneal Inlay (ACI) is intended to improve near vision in patients with presbyopia, which is the loss of near vision, and reduce dependency on reading glasses. Eye Health / Blindness Fri, 06 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/170038.php http://www.medicalnewstoday.com/articles/170038.php Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) announced that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial. The double-blind and placebo-controlled Phase II trial is underway at multiple centers in Germany and Sweden. Cervical Cancer / HPV Vaccine Fri, 06 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/170039.php http://www.medicalnewstoday.com/articles/170039.php Cephalon, Inc. (Nasdaq: CEPH) announced the journal Cancer has published a pivotal study demonstrating that TREANDA® (bendamustine HCl) for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma (NHL) whose disease had progressed during or within six months of treatment with rituximab. Lymphoma / Leukemia / Myeloma Fri, 06 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/170041.php http://www.medicalnewstoday.com/articles/170041.php Amgen (Nasdaq: AMGN) announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival. Colorectal Cancer Fri, 06 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/170042.php http://www.medicalnewstoday.com/articles/170042.php Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced that a new peer-reviewed clinical study published in this month's Inhalation Toxicology demonstrates that Masimo Rainbow SET® Pulse CO-Oximetry (SpCO) provides reliable measurements of carbon monoxide (CO) in the blood that facilitate fast, accurate diagnosis of CO poisoning in pre-hospital emergency and rescue environments. Blood / Hematology Fri, 06 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/170043.php http://www.medicalnewstoday.com/articles/170043.php Two studies published by the Southwest College of Naturopathic Medicine in the October issue of BMC Clinical Pharmacology investigated the use of oral dimercaptosuccinic acid (DMSA), a prescription medicine approved by the FDA for treating lead poisoning, and used off-label in these studies for treating heavy metal toxicity in children with autism. In the investigations, DMSA was given to 65 children with autism (ages 3 -8 years) to determine its effects. Autism Fri, 06 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/170046.php http://www.medicalnewstoday.com/articles/170046.php Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Lymphoma / Leukemia / Myeloma Fri, 06 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/170051.php http://www.medicalnewstoday.com/articles/170051.php The November issue of European Urology, the official journal of the European Association of Urology, features an article focussing on prostate specific antigen (PSA) velocity and early cancer detection. It has been suggested that changes in PSA over time aid prostate cancer detection. It is argued that a rapidly rising PSA may indicate a greater risk of diagnosis of prostate cancer even if PSA levels are low. Prostate / Prostate Cancer Fri, 06 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/170054.php http://www.medicalnewstoday.com/articles/170054.php A study of 2,203 cardiac surgery patients from Veterans Affairs (VA) medical centers nationwide revealed that coronary-artery bypass grafting (CABG) completed "off-pump," meaning without a heart-lung machine, had no advantages in patient outcomes compared to the traditional "on-pump" procedure. A. Laurie Shroyer, Ph.D. Cardiovascular / Cardiology Fri, 06 Nov 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/170008.php http://www.medicalnewstoday.com/articles/170008.php This past October, 214 researchers from the U.S., Europe, and Australia, as well as representatives of families with aggressive genetic forms of Alzheimer disease (AD), met at Washington University, St. Louis, Missouri, to devote two intense days of talks and discussion to their goal of detecting this disease before symptoms appear. Alzheimer's / Dementia Thu, 05 Nov 2009 21:00:00 PST http://www.medicalnewstoday.com/articles/170000.php http://www.medicalnewstoday.com/articles/170000.php Antigenics, Inc. (NASDAQ: AGEN) today indicated that GlaxoSmithKline's (GSK) Phase III malaria vaccine clinical trial, containing Antigenics' QS-21 Stimulon® adjuvant, has enrolled more than 5,000 children to date and is expected to involve up to 16,000 children. The pivotal efficacy study of RTS,S, the world's most clinically advanced malaria vaccine, is ongoing in seven African countries. Tropical Diseases Thu, 05 Nov 2009 20:00:00 PST http://www.medicalnewstoday.com/articles/169998.php http://www.medicalnewstoday.com/articles/169998.php Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today patient enrollment is complete in three of its late-stage clinical trials. "We are pleased to be executing on our strategic plan with the achievement of these patient enrollment milestones in the clinical development programs for denufosol, PROLACRIA™ and AZASITE®, as this places us in a position to have top-line results from all our late-stage clinical programs within 18 months. Cystic Fibrosis Thu, 05 Nov 2009 16:00:00 PST http://www.medicalnewstoday.com/articles/169991.php http://www.medicalnewstoday.com/articles/169991.php BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole Lauriad® at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia (October 29 - November 1st). Infectious Diseases / Bacteria / Viruses Thu, 05 Nov 2009 12:00:00 PST http://www.medicalnewstoday.com/articles/169976.php http://www.medicalnewstoday.com/articles/169976.php Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., announced data from a Phase 2 clinical trial of Hematide™ showing that Hematide increased hemoglobin and reduced or eliminated the need for blood transfusion in most patients with erythropoietin-induced pure red cell aplasia (PRCA). The data were published in the 5th November 2009 issue of the New England Journal of Medicine. Blood / Hematology Thu, 05 Nov 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/169977.php http://www.medicalnewstoday.com/articles/169977.php Most weight-control strategies emphasize energy-restricted diets and increased physical activity - and most are not effective over the long term. In a study of a "weight-acceptance" intervention, published in the November 2009 issue of the Journal of the American Dietetic Association, researchers found that there could be long-term beneficial effects on certain eating behaviors using a weight- acceptance intervention approach. Obesity / Weight Loss / Fitness Thu, 05 Nov 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/169979.php http://www.medicalnewstoday.com/articles/169979.php Scientists are reporting development of a nano-size capsule that boosts the body's uptake of curcumin, an ingredient in yellow curry now being evaluated in clinical trials for treatment of several diseases. Their study is in ACS' Journal of Agricultural and Food Chemistry, a bi-weekly publication. Koji Wada and colleagues note that curcumin is a potent antioxidant found in the spice, turmeric. Nutrition / Diet Thu, 05 Nov 2009 04:00:00 PST http://www.medicalnewstoday.com/articles/169942.php http://www.medicalnewstoday.com/articles/169942.php Researchers at Fox Chase Cancer Center found that radiation treatment for women who had a lumpectomy for early-stage breast cancer can be safely reduced to four weeks, instead of the usual six to seven weeks, by delivering a higher daily dose - greatly reducing the length of treatment time. The five-year results of the phase II study were presented at the annual meeting of the American Society for Radiation Oncology. Breast Cancer Thu, 05 Nov 2009 04:00:00 PST http://www.medicalnewstoday.com/articles/169944.php http://www.medicalnewstoday.com/articles/169944.php New Formula Calculates More Accurate 'Lung Age' in Smokers (#7896 ) A new formula more accurately calculates a smoker's "lung age," which researchers hope will help persuade patients to quit the habit. A research team from Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, CA, developed and evaluated a new lung age formula based on %FEV1/FEV6 rather than the current lung age formulas based on height and FEV1 or FVC. Smoking / Quit Smoking